The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia.
Shamila GinigeJames DalyCatherine HylandTanya PowleyHelen O'BrienAna M MorenoGlenn GardenerRobert FlowerPublished in: The Australian & New Zealand journal of obstetrics & gynaecology (2021)
Maternal alloimmunisation against red blood cell antigens can cause haemolytic disease of the fetus and newborn (HDFN). Although most frequently caused by anti-D, since the implementation of rhesus D (RhD) immunoglobulin prophylaxis, other alloantibodies have become more prevalent in HDFN. Recent advances in non-invasive prenatal testing (NIPT) have allowed early prediction of HDFN risk in alloimmunised pregnancies and allow clinicians to focus health resources on those pregnancies that require intervention. This article aims to provide updates on the current status of NIPT in Australia as both a diagnostic and screening tool in pregnancy.
Keyphrases
- pregnancy outcomes
- red blood cell
- pregnant women
- preterm birth
- current status
- healthcare
- gestational age
- birth weight
- randomized controlled trial
- public health
- primary care
- mental health
- dendritic cells
- palliative care
- quality improvement
- health information
- immune response
- body mass index
- health promotion
- risk assessment
- social media